Triptorelin

• TRAP study: Testosterone for Androgen Receptor Polymorphism. Not authorised
  2024-510596-37-00 Phase IV 1 country Instituto Bernabeu S.L.
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 Phase II 1 country Azienda Provinciale Per I Servizi Sanitari
• TRAP study: Testosterone for Androgen Receptor Polymorphism. Pending
  2024-510596-37-01 Phase III 1 country Instituto Bernabeu S.L.
• Intranasal nafarelin compared to subcutaneous triptorelin for triggering final oocyte maturation in ovarian stimulation: a non-inferiority r… Pending
  2024-516621-31-00 Phase IV 1 country Santiago Dexeus Font Fundacio Privada
• ProFertil Pending
  2024-518977-32-00 Phase III 1 country Karolinska University Hospital
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 Phase III 7 countries Unicancer
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T… Pending
  2024-520093-34-00 Phase III 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
• COMPASS - COpenhagen MenoPAuSe Study Pending
  2025-522558-37-00 Phase II 1 country Region Hovedstaden
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 Phase III 5 countries Unicancer
• Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis: Randomised Prospective Study. Recruiting
  2024-519126-20-00 Phase III/IV 1 country Hospital Foch
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 Phase II/III 2 countries Ziekenhuis Aan De Stroom
• Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial Recruiting
  2025-522525-34-00 Phase IV 1 country Santiago Dexeus Font Fundacio Privada
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-509787-15-00 Phase III 2 countries Unicancer
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-507482-26-00 Phase III 4 countries Unicancer
• Ovulation induction and luteal phase support with GnRH agonists in in vitro fertilization Recruiting
  2023-505126-34-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting
  2023-506698-36-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• INtensity of OVarian stimualtion and Euploid Embryos (INOVEE Study) Recruiting
  2023-507028-22-00 Phase IV 1 country Santiago Dexeus Font Fundacio Privada
• PRO_NAT Recruiting
  2023-504188-18-00 Phase IV 1 country Instituto Bernabeu S.L.
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence… Recruiting
  2024-517666-41-00 Phase III 1 country Instituto De Investigacion En Oncología Radioterapica FEOR
• Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting
  2022-502373-42-00 Phase III 1 country UZ Leuven
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended
  2023-506717-21-00 Phase I/II 6 countries Novartis Pharma AG
• A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended
  2024-512023-37-00 Phase II 1 country Ziekenhuis Aan De Stroom

Showing 1–24 of 31 trials